Mark Flower has 20 years’ experience in cell and gene therapy, immunotherapy, cell therapy manufacturing, apheresis cell collections, and bioprocessing.

Currently VP of business development with Cryoport Systems, Mark recently served as VP of business development with Cellares, a company developing a fully automated and closed end-to-end platform for manufacturing cell-based therapeutics. Previous roles include VP of business development and strategic relationships with Be The Match BioTherapies (BTMB), a National Marrow Donor Program subsidiary. Prior to BTMB, he served as Executive Director of Sales and Marketing at Hitachi Chemical Advanced Therapeutics Solutions (now Minaris Regenerative Medicine), a leading cell therapy CDMO. Earlier in his career, Mark worked in the Therapeutic Systems business unit at Terumo BCT where he launched multiple tools and technologies into the cell therapy arena. Notably, he launched the first MNC collection protocol (leukapheresis collection) on the Spectra Optia Apheresis System into Europe in 2008, and subsequently the U.S. He also led the commercialization and global product launch of the Quantum Cell Expansion System.

Mark is currently a member of the International Society for Cell and Gene Therapy (ISCT) North America Executive Committee and holds a seat on ISCT’s Business Development and Finance Committee.